The Decentralized Trials & Research Alliance (DTRA) today announced that it now counts more than 100 member organizations united in the shared mission to make clinical-trial participation widely accessible to patients. DTRA is the largest and only multi-stakeholder initiative focused on the global adoption of decentralized research methodology.
Ranging from life-sciences research companies to patient advocacy organizations, technology and service providers, and leading regulatory authorities, such as the U.S. Food and Drug Administration, the 100+ DTRA members are engaged in advancing policies, research practices and technologies that will accelerate the global adoption of patient-focused, inclusive, decentralized clinical trials and research.
“The commitment of these organizations and their reach and scale underscore our collective potential for advancing decentralized research,” said Amir Kalali, MD, co-chair of DTRA, life sciences executive, and founder of several collaborative life science communities.
“While the COVID-19 pandemic accelerated the adoption of decentralized research, we are now seeing the commitment of the research community working together to become a core resource in the clinical research toolkit,” said Craig Lipset, DTRA co-chair, clinical innovation advisor, and a pioneer in decentralized trials. “We are proud that the DTRA can serve as the center for the future of decentralized research.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!